- Home
- GYRE vs DGICA Comparison
GYRE vs DGICA Comparison
Compare GYRE & DGICA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GYRE | DGICA |
|---|---|---|
| Founded | 2002 | 1986 |
| Country | United States | United States |
| Employees | N/A | 851 |
| Industry | Biotechnology: Pharmaceutical Preparations | Property-Casualty Insurers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 759.1M | 639.0M |
| IPO Year | 2004 | N/A |
Fundamental Metrics
Financial Performance| Metric | GYRE | DGICA |
|---|---|---|
| Price | $8.33 | $17.64 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 2 | 1 |
| Target Price | $17.00 | ★ $19.50 |
| AVG Volume (30 Days) | 58.7K | ★ 106.5K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | ★ 4.12% |
| EPS Growth | ★ 103.55 | N/A |
| EPS | ★ 0.04 | N/A |
| Revenue | ★ $275,000.00 | N/A |
| Revenue This Year | $11.59 | $2.26 |
| Revenue Next Year | $26.31 | $2.96 |
| P/E Ratio | $214.38 | ★ $7.82 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.11 | $16.50 |
| 52 Week High | $13.47 | $21.06 |
Technical Indicators
Market Signals| Indicator | GYRE | DGICA |
|---|---|---|
| Relative Strength Index (RSI) | 53.69 | 38.65 |
| Support Level | $6.94 | $16.51 |
| Resistance Level | $9.31 | $19.39 |
| Average True Range (ATR) | 0.37 | 0.54 |
| MACD | 0.03 | -0.06 |
| Stochastic Oscillator | 48.89 | 42.73 |
Price Performance
Historical ComparisonAbout GYRE Gyre Therapeutics Inc.
Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.
About DGICA Donegal Group Inc.
Donegal Group Inc is an insurance holding company that offers businesses and individuals personal and commercial lines of property and casualty insurance. The company's reportable segments are its Investment function, Personal lines of insurance, and Commercial lines of insurance. Personal lines products consist mainly of homeowners and private passenger automobile policies. The Commercial lines products of its insurance subsidiaries consist mainly of commercial automobile, commercial multi-peril, and workers' compensation policies. The group mainly operates in the United States.